Seeking Alpha
 

Amgen Inc. (AMGN)

- NASDAQ
  • May. 17, 2011, 10:53 AM
    Another favorable trial for Amgen's (AMGN) denosumab drug, used in men to treat prostate cancer, as it's seen to delay bone pain in patients. A fall study showed surprisingly good results; analysts expect the drug's annual sales to reach $2.5B by 2015.
    | Comment!
  • Apr. 20, 2011, 4:09 PM
    Amgen (AMGN): Q1 EPS of $1.34 beats by $0.05. Revenue of $3.7B in-line. Shares +0.6% AH. (PR)
    | Comment!
  • Apr. 20, 2011, 12:10 AM
    Notable earnings after Wednesday's close: AAPL, AMGN, AMR, AXP, BSX, CAKE, CMG, CVA, ESV, ETFC, FFIV, GILD, KNX, LRCX, MAR, NE, NFX, PBCT, QCOM, RRR, SLM, TEX, WDC, WLT, YUM
    | Comment!
  • Mar. 24, 2011, 2:25 PM
    Amgen (AMGN +1%) may introduce its first dividend at an April 21 investor meeting, Bloomberg says, boosting a stock whose value has been chopped by a third since 2006. Unlike other biotechs, Amgen can afford to return money to shareholders because it generates a lot of cash compared with capital expenditures. But the projected 2.3% yield would rank well behind drugmakers PFE, MRK and JNJ.
    | 1 Comment
  • Feb. 11, 2011, 2:10 PM
    JPMorgan analysts pick 16 stocks they think will perform well if there's an onset of rapid inflation: NEM, ABX, PFE, TEVA, MRK, CVS, FCX, ABT, APA, AMGN, GILD, WLP, AET, COV, CI, BTU.
    | 1 Comment
  • Feb. 2, 2011, 7:28 AM
    The incredible shrinking blockbuster? Roche (RHHBY.PKreported disappointing full-year earnings and cut its outlook for its key cancer drug Avastin as regulators and doctors reexamine the use of the drug.
    | Comment!
  • Jan. 24, 2011, 4:16 PM
    Amgen (AMGN): Q4 EPS of $1.17 beats by $0.06. Revenue of $3.8B (+1% Y/Y) beats by $35M. Shares +1.1% AH. (PR)
    | Comment!
  • Jan. 24, 2011, 12:10 AM
    Notable earnings after Monday's close: AXP, AMGN, CSX, JEC, SANM, STM, TXN, VMW, ZION
    | Comment!
  • Dec. 31, 2010, 7:51 AM
    The FDA approved around 21 drugs in 2010, a relatively modest figure, with some of the most highly anticipated products delayed into next year or beyond. Among this year's FDA-approval winners: Amgen (AMGN), Roche (RHHBY.PK), Novartis (NVS), Acorda (ACOR) and Dendreon (DNDN).
    | Comment!
  • Dec. 21, 2010, 3:23 PM
    Xoma (XOMA +71%) shares skyrocket after a research report says the company’s once-a-month diabetes drug could lead a potential blockbuster class of drugs. Xoma's IL-1 inhibitor could give it an edge among competitors including Novartis (NVS), Amgen (AMGN) and Eli Lilly (LLY), according to Sumner Street Research.
    | 2 Comments
  • Dec. 14, 2010, 9:00 AM
    Premarket gainers: GXDX +17%. AMGN +4%. BP +4%.
    Losers: LCI -13%. BBY -13%. LPH -12%. ICO -11%. LXRX -10%. YMI -8%. AHT -6%. OXPS -5%. VECO -5%. REE -5%. WPZ -4%.
    | Comment!
  • Dec. 14, 2010, 8:10 AM
    Shares of Amgen (AMGN) are +6.7% premarket after the company's disclosure yesterday evening that its bone drug denosumab delayed the spread of prostate cancer to bones in a clinical trial. Analysts had expected a less favorable trial result.
    | Comment!
  • Oct. 26, 2010, 7:52 AM
    Savient's (SVNT +4.4%) 44% drop yesterday may have been just what suitors were waiting for. With shares now trading near $12, potential bidders (like ABT, PFE, AMGN) might come back to the table and fair value may turn out to be closer to $20/share than the $47/share target some analysts had previously suggested.
    | Comment!
  • Oct. 25, 2010, 4:22 PM
    Amgen (AMGN): Q3 EPS of $1.36 beats by $0.09. Revenue of $3.8B (+0.1%) in-line. Shares -0.1% AH. (PR)
    | 1 Comment
  • Oct. 25, 2010, 12:10 AM
    Notable earnings after Monday's close: AMGN, ATHR, COG, DDR, EW, MAS, PCL, SLG, SNV, TXN, VECO, VRTX
    | Comment!
  • Oct. 20, 2010, 4:53 PM
    Stocks are "incredibly cheap" compared to bonds, Legg Mason's Bill Miller says - in fact, "It's the best time since the early 1980s" to buy stocks. His favorite picks now include: Merck (MRK), Amgen (AMGN), Hewlett-Packard (HPQ), Intel (INTC), Goldman Sachs (GS), Wells Fargo (WFC).
    | 11 Comments
Visit Seeking Alpha's
AMGN vs. ETF Alternatives
Company Description
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics.
Sector: Healthcare
Industry: Biotechnology
Country: United States